Free Trial

Certara, Inc. (NASDAQ:CERT) Shares Sold by Bank of New York Mellon Corp

Certara logo with Medical background

Bank of New York Mellon Corp lessened its stake in Certara, Inc. (NASDAQ:CERT - Free Report) by 27.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,447,744 shares of the company's stock after selling 547,327 shares during the period. Bank of New York Mellon Corp owned 0.90% of Certara worth $14,333,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in CERT. Janney Montgomery Scott LLC acquired a new stake in Certara in the first quarter worth about $120,000. First Trust Advisors LP acquired a new stake in Certara in the fourth quarter worth about $140,000. Illinois Municipal Retirement Fund boosted its holdings in Certara by 3.9% in the first quarter. Illinois Municipal Retirement Fund now owns 59,721 shares of the company's stock worth $591,000 after acquiring an additional 2,268 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Certara in the fourth quarter worth about $3,628,000. Finally, Northern Trust Corp boosted its holdings in Certara by 14.0% in the fourth quarter. Northern Trust Corp now owns 877,010 shares of the company's stock worth $9,340,000 after acquiring an additional 108,038 shares in the last quarter. Hedge funds and other institutional investors own 73.96% of the company's stock.

Wall Street Analysts Forecast Growth

CERT has been the subject of a number of research reports. Morgan Stanley initiated coverage on Certara in a report on Thursday, July 3rd. They set an "equal weight" rating and a $16.00 target price for the company. Barclays raised Certara from an "equal weight" rating to an "overweight" rating and lifted their target price for the stock from $11.00 to $14.00 in a report on Thursday, May 8th. JMP Securities reaffirmed a "market perform" rating on shares of Certara in a report on Tuesday, May 6th. KeyCorp decreased their target price on Certara from $18.00 to $15.00 and set an "overweight" rating for the company in a report on Monday, July 14th. Finally, Robert W. Baird lifted their target price on Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a report on Friday, April 11th. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, Certara presently has an average rating of "Moderate Buy" and a consensus target price of $15.29.

Get Our Latest Research Report on CERT

Certara Price Performance

Shares of NASDAQ:CERT traded up $0.40 during midday trading on Tuesday, reaching $10.54. 640,090 shares of the company's stock traded hands, compared to its average volume of 1,497,928. Certara, Inc. has a 1 year low of $8.64 and a 1 year high of $16.61. The company has a market cap of $1.71 billion, a P/E ratio of -525.25 and a beta of 1.43. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.78 and a current ratio of 2.78. The company has a fifty day simple moving average of $11.29 and a two-hundred day simple moving average of $11.88.

Certara (NASDAQ:CERT - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.10 by $0.04. Certara had a positive return on equity of 5.05% and a negative net margin of 0.67%. The firm had revenue of $106.00 million during the quarter, compared to the consensus estimate of $104.44 million. During the same period in the prior year, the company earned $0.10 EPS. The firm's revenue was up 9.7% compared to the same quarter last year. Equities analysts predict that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Certara Company Profile

(Free Report)

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.

See Also

Institutional Ownership by Quarter for Certara (NASDAQ:CERT)

Should You Invest $1,000 in Certara Right Now?

Before you consider Certara, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Certara wasn't on the list.

While Certara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

AI Stocks Are Printing Money — These 3 Are Just Getting Started
Why Drone Stocks Are Skyrocketing Right Now!
Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines